Compare RGP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | CGEN |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 143.1M |
| IPO Year | 2006 | 2000 |
| Metric | RGP | CGEN |
|---|---|---|
| Price | $5.13 | $1.48 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 310.6K | ★ 405.6K |
| Earning Date | 01-07-2026 | 11-10-2025 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $534,625,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $1.13 |
| 52 Week High | $9.96 | $2.66 |
| Indicator | RGP | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 40.30 |
| Support Level | $5.14 | $1.47 |
| Resistance Level | $5.30 | $1.55 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 40.74 | 16.98 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.